Pfizer released the results of its clinical trials examining the occurrence of heart inflammation in children who received the COVID-19 vaccine.

While the results acknowledged heart-related symptoms present in some of the vaccine recipients, none were linked to myocarditis.

Researchers assessed the participants’ levels of troponin I, which is linked to heart damage, before and after individuals aged 5-30 received the vaccine.

The clinical trial found that “troponin levels were rarely elevated” and were similar both before and after vaccination. One trial participant, however, received an electrocardiogram after having chest pain and breathing problems. This individual also had high troponin levels.

“No myocarditis or pericarditis cases were reported,” according to the researchers. “These findings did not provide evidence that BNT162b2 causes troponin elevations.”

The researchers noted in the report that some of the participants’ troponin levels were “not reported.”

American Faith reported that Pfizer’s sales of its COVID-19 vaccine declined by 70% in 2023, according to a report to the U.S. Securities Exchange Commission.

Pfizer’s total revenues decreased 42%, down to $58.5 billion from $100.33 billion.